Yes, Keynote 200 (Cavatak/Keytruda) includes a study with non...

  1. 95 Posts.
    lightbulb Created with Sketch. 16
    Yes, Keynote 200 (Cavatak/Keytruda) includes a study with non small cell lung cancer. Lots of other companies are running Phase 3 trials with a chemo/PD1 combos. We need to get in there too!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.